[Results of monotherapy with terazosin (kornam) in chronic infectious prostatitis patients].
OBJECTIVE
To evaluate effectiveness of alpha 1-adrenoblockers (a1-AB) in patients with chronic non-infectious prostatitis (CP).


METHODS
a1-AB effectiveness was studied in 28 volunteers with non-infectious CP (type IIIA). All the patients received terazosin (kornam, Slovenia) in a dose 5 mg/day after dose titration for 2-3 weeks (the initial dose was 1 mg/day). The assessment of the efficiency was standard with the use of frequency and severity of symptoms scales as well as questionnaire NIH CPSI.


RESULTS
Symptomatic improvement was achieved in 27 patients (96%). Dysuria and intensity of pain diminished in 24 (82%) and 26 (93%) patients. Voiding disorders proved most sensitive to a1-AB. Quality of life rose 2-fold. Probability of the recurrence 1 month after terazosin therapy was 0.29, after 6 months--0.43. Recurrent dysuria occurred in 33%, pain--in 58%.


CONCLUSIONS
Terazosin monotherapy in patients with non-infectious CP results in reduction of the symptoms severity and pollakiuria frequency, frequency of recurrences and in improvement of quality of life. a1-AB in CP do not prevent recurrence in half the cases but the symptoms severity in recurrent disease is much weaker.
Lopatkin
N A
NA
Apolikhin
O I
OI
Sivkov
A V
AV
Oshchepkov
V N
VN
Egorov
A A
AA
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D002908:Chronic Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D011472:Prostatitis / Q000188:drug therapy*; D011788:Quality of Life
D058668:Adrenergic alpha-1 Receptor Antagonists; D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin